ATHX Athersys Inc

0.1018

0.00 (0.00%)

Pre Market

Last Updated: 01:00:00

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Athersys Inc	NASDAQ:ATHX	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	0.1018	0.101	0.104				0	01:00:00

EDISON EQUITY RESEARCH: ATHERSYS

26/10/2015 3:29am

InvestorsHub NewsWire

EDISON EQUITY RESEARCH: ATHERSYS - ONE DOOR CLOSES, ANOTHER ONE OPENS

Today, Athersys announced that the agreement between the company and Chugai to develop and commercialize MultiStem in Japan has ended following the failure of negotiations to modify the financial terms of the agreement and to decide on a development strategy. However, Athersys also announced that it has already signed a letter of intent with another Japanese company to develop and commercialize MultiStem in Japan in ischemic stroke and other areas.

Athersys is a US biotech company developing MultiStem (allogeneic, bone marrow-derived stem cells). A Phase II trial with MultiStem in ischemic stroke has completed, while further studies in AMI (Phase II) and ARDS (Phase IIa) are planned.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports